Navigation Links
Adeona Announces Second Quarter 2010 Profitability and Achievements
Date:8/16/2010

eases are primarily due to the increased costs associated with the operation of Adeona Clinical Laboratory, which was acquired in the third quarter of 2009 and therefore did not have any impact on our expenses during the first and second quarter of 2009. Research and development expenses for the three and six months ended June 30, 2010, also include a non-cash charge of $18,487 and $52,967, compared to $63,293 and $119,610 for the same period in 2009, relating to share-based compensation expense.

General and administrative expenses were $659,127 and $1,388,312 for the three and six months ended June 30, 2010, respectively, compared to $473,961 and $1,093,864 for the same periods in 2009.  These increases are primarily the result of increased consultant fees and salary expenses. For the three and six months ended June 30, 2010, general and administrative expenses included a non-cash charge of $32,460 and $183,607, respectively, compared to $35,406 and $70,633 for the same periods in 2009, relating to share-based compensation expense.

Net income for the three months ended June 30, 2010, was $979,782 or $0.04 per share, compared to a net loss of ($879,550) or ($0.04) per share for the same period in 2009.  Net loss for the six months ended June 30, 2010, was ($107,740) or ($0.00) per share, compared to ($1,992,825) or ($0.09) per share for the same period in 2009.  

As of June 30, 2010, Adeona had approximately $3.3 million in cash compared to approximately $2.7 million on December 31, 2009.  

Adeona's recent achievements include the following:

  • On May 7, 2010, Adeona announced that it had entered into a corporate partnership with Sweden-based Meda AB, to develop flupirtine for the treatment of fibromyalgia syndrome. Meda will assume all future development costs. Adeona is entitled to receive royalties on net sales of flupirtine for fibromyalgia and milestone payments of $
    '/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adeona Announces HartLab Expansion Into Microbiology Testing Services
2. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 7 Novartis Pharmaceuticals Corporation today announced the ... 0.5 mg daily, a first-line oral treatment for ... by the US Food and Drug Administration (FDA) ... with MS and healthcare professionals seeking information about ...
... Privigen®, the first and only 10% ... is effective and well tolerated in patients with ... presented today at the XIVth Meeting of the ... Privigen offers significant protection against infection. ...
Cached Medicine Technology:Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 2Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 3Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 4Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 5Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 6Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 7Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show 2Privigen® Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show 3
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... Population Council scientists and their partners have found that ... prevent the transmission of multiple sexually transmitted infections (STIs) ... herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). ... the gel is effective against multiple strains of HIV, ... against all three viruses of at least eight hours ...
(Date:4/17/2014)... world is less than 40 years away from a ... and governments, according to a top scientist at the ... in human history, food production will be limited on ... and energy," said Dr. Fred Davies, senior science advisor ... could become as politically destabilizing by 2050 as energy ...
(Date:4/17/2014)... Patrick Johnston, whose work has transformed cancer care in ... the European Academy of Cancer Sciences., The Academy, which ... of highly distinguished oncologists and cancer researchers which aims ... in Europe. , Professor Johnston, whose leadership has seen ... bottom of the UK league table to near the ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2
... marketed as Revatio, study finds , TUESDAY, May 18 ... that causes progressive scarring of the lung tissue might ... Viagra, a new study finds. , The disease, called ... thick and stiff, reducing the ability to breathe. There,s ...
... life, study finds , TUESDAY, May 18 (HealthDay News) -- ... hurt feelings. Now, new research shows that a warm, caring ... growing up poor -- protection that can last well into ... with a higher risk for heart disease and other mental ...
... of the University of Helsinki, and Oncos Therapeutics, the ... next generation oncolytic viruses, published initial results from their ... The therapy program is based on scientific research at ... for ongoing clinical development. The results demonstrate ...
... the care they provide can vary widely depending upon the ... to a new RAND Corporation study. Researchers say the ... cost profiles that are being created by insurance companies in ... study provides more evidence that efforts to create physician cost ...
... will allow researchers to conduct larger, more effective studies ... in the United States. With a ... and Reinvestment Act of 2009, Cincinnati Children,s Hospital Medical ... (REGID). The first of its kind registry ...
... ... ever before. Get the facts on cancer and ways to prevent it from the Pulitzer ... ... the nation in the prevention and treatment of cancer. Truecancerfacts.com was written by Pulitzer Prize ...
Cached Medicine News:Health News:Viagra May Aid Those With Lung Fibrosis 2Health News:Viagra May Aid Those With Lung Fibrosis 3Health News:A Mother's Love Overcomes Poverty's Effect on Health 2Health News:A Mother's Love Overcomes Poverty's Effect on Health 3Health News:Oncolytic viruses mediating anti-tumor immunity in human cancer patients 2Health News:Results of physician cost profiling can vary widely, study finds 2Health News:National registry to track eosinophilic disorders 2Health News:What Doctors Won't Tell Their Patients About Cancer 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: